Monitor this situation.
Unsubscribe anytime.
[SITUATION] · [ACTIVE] · [BUSINESS]
2 clusters · 4 sources · 14 days · First seen · Last updated
Cell and gene therapy industry development
Overview
The cell and gene therapy (CGT) sector is shifting its focus from scientific validation toward overcoming logistical, economic, and manufacturing hurdles. Initially, industry discussions centered on the need for integrated ecosystems and shared standards to ensure patient access and affordability as therapies move toward more common medical conditions.
As the sector evolves, the manufacturing market is projected to see significant growth, potentially increasing from $9.48 billion in 2025 to $212.8 billion by 2030. This expansion is driven by a demand for treatments for cancer and neurological disorders that currently exceeds existing production capacities. In response, major industry players are expanding production, and US government agencies like ARPA-H are launching programs to improve biomanufacturing yields and cost-effectiveness. Additionally, new technical initiatives, such as aseptic spray drying programs, are being developed to address challenges in the stability and delivery of biologics.
Entities
Business Group on Health · Institute for Clinical and Economic Review · Samsung Biologics · Thermo Fisher Scientific · Sarah Emond
Timeline
-
[BUSINESS] 2 sourcesCell and gene therapy manufacturing market projected to reach $212.8 billion by 2030
The cell and gene therapy manufacturing market is expected to reach $212.8 billion by 2030, while Lonza advances aseptic spray drying technology to improve biologic drug delivery.
-
[HEALTH] 2 sourcesCell and gene therapy sector faces infrastructure and affordability challenges
The cell and gene therapy industry is shifting focus toward building the collaborative infrastructure and economic models necessary to deliver advanced treatments to wider patient populations at scale.
Sources
dreamnews.jp · genengnews.com · manufacturingchemist.com · podtech.net